Table 1.
Patient characteristics
| No dyspnea (n = 41) | Dyspnea (n = 35) | |
|---|---|---|
| Demographics | ||
| Age | 60 ± 16 | 63 ± 16 |
| Male | 27 (66) | 20 (57) |
| Ever smoker | 10 (25) | 13 (37) |
| Comorbidities | ||
| Cardiac | 4 (10) | 10 (29) |
| Pulmonary | 6 (15) | 10 (29) |
| Renal | 2 (5) | 5 (14) |
| Diabetes | 11 (27) | 7 (20) |
| Hypertension | 15 (37) | 11 (31) |
| Dyslipidemia | 12 (29) | 12 (34) |
| Malignancy | 4 (10) | 4 (11) |
| COVID-19 infection characteristics | ||
| Admission to hospital | 40 (98) | 34 (97) |
| Length of admission in days | 6.5 (5–11) | 11 (5–17) |
| Length of oxygen requirements in days | 5 (3–11) | 11 (7–19) |
| ICU/HAU admission | 19 (46) | 17 (49) |
| Mechanical ventilation | 7 (17) | 6 (17) |
Data shown are mean ± standard deviation, median (interquartile range), or number (%). Dyspnea was defined as a UCSD score > 10 at 12 months post-COVID-19. Pulmonary comorbidity was defined as any formally diagnosed lung parenchymal, pulmonary vascular, pleural, airway, or sleep-related abnormality. Cardiac comorbidity was defined as any formally diagnosed coronary artery disease, valvular abnormality, heart failure, cardiomyopathy, or arrythmia. Malignancy was defined as any formally diagnosed malignant tumour